Effects of PCSK9 inhibitors on metabolic-associated fatty liver disease: a short review
Metabolic-associated fatty liver disease (MAFLD), previously known as non-alcoholic fatty liver disease, is a significant epidemiological problem and a well-known cardiovascular risk factor. The increasing number of cases creates the need for new therapeutic methods aimed at improving patient outcom...
Saved in:
Main Authors: | Ewelina Jakielska, Paweł Głuszak, Marta Walczak, Wiesław Bryl |
---|---|
Format: | Article |
Language: | English |
Published: |
Termedia Publishing House
2023-03-01
|
Series: | Gastroenterology Review |
Subjects: | |
Online Access: | https://www.termedia.pl/Effects-of-PCSK9-inhibitors-on-metabolic-associated-fatty-liver-disease-a-short-review,41,50394,1,1.html |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PCSK9-antibodies fail to block PCSK9-induced inflammation in macrophages and cannot recapitulate protective effects of PCSK9-deficiency in experimental myocardial infarction
by: Simon Rauterberg, et al.
Published: (2025-01-01) -
PCSK9 in T-cell function and the immune response
by: Yuying Wang, et al.
Published: (2024-12-01) -
Metabolic and Genetic Determinants of Lipid Metabolism Disruption in Non-Alcoholic Fatty Liver Disease
by: O. Yu. Kytikova, et al.
Published: (2020-05-01) -
Conditional knockdown of hepatic PCSK9 ameliorates high-fat diet-induced liver inflammation in mice
by: Xue-Ying Zhang, et al.
Published: (2025-02-01) -
Profile of Children With Non-alcoholic Fatty Liver Disease Referred to a Hospital in Iran
by: Amin Ghanbari, et al.
Published: (2024-12-01)